Cedilla is developing small-molecule therapeutics that conditionally modulate important, yet elusive cancer targets based on understanding the disease-relevant functional states of these proteins.
Mainstream approaches to drug discovery offer a limited view of proteins as static entities and focus on a single and simplified state.
Cedilla recognizes that proteins are functionally dynamic.
An integrated suite of capabilities enables Cedilla to understand how interactions within the cellular environment critically modulate their activity.
Cedilla characterizes the native full-length protein with relevant post-translational modifications (PTMs), protein-protein interactions (PPIs) and sub-cellular localization.
By understanding proteins in their functional state, Cedilla is discovering previously unrecognized small molecule binding sites to access key cancer drivers that have been considered undruggable.
Learn more about our conditional inhibitors »